Sign in
Shahar Keinan

Shahar Keinan

Partner and Analyst at Brosh Capital Partners

Israel

Shahar Keinan is a Partner and Analyst at Brosh Capital Partners, where he specializes in public equity investments with a focus on turnaround opportunities in companies such as Kamada, Alcobra Pharmaceuticals, Perion Network, Matomy Media Group, and Kenon Holdings. He has played a key role in active investments that have influenced company management and contributed to visible share price movements, such as Brosh’s strategic acquisition of a 6.2% stake in Kamada Ltd. No public third-party rankings or returns data are available, but public disclosures confirm hands-on involvement in major transactions. Shahar Keinan joined Brosh Capital Partners as a founding team member and partner, bringing expertise in equity analysis and investment strategy, although no specific FINRA licenses or securities credentials are listed in public records.

Shahar Keinan's questions to Kenon Holdings (KEN) leadership

Question · Q2 2019

Shahar Keinan of Brosh Capital Partners questioned the high level of Kenon's standalone G&A expenses and requested an update on the Qoros sale timetable.

Answer

Executive Robert Rosen clarified that the elevated G&A is driven by ongoing litigation and arbitration costs from retained claims, not one-time effects, making it difficult to forecast. Regarding the Qoros sale, Rosen stated there is no definitive timetable due to the unpredictable nature of the Chinese regulatory approval process.

Ask follow-up questions

Fintool

Fintool can predict Kenon Holdings logo KEN's earnings beat/miss a week before the call